{'52WeekChange': 0.48849106,
 'SandP52WeekChange': 0.0644362,
 'address1': '14193 NW 119th Terrace',
 'address2': 'Suite 10',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.1,
 'askSize': 1000,
 'averageDailyVolume10Day': 294862,
 'averageVolume': 412096,
 'averageVolume10days': 294862,
 'beta': 2.691316,
 'beta3Year': None,
 'bid': 5.74,
 'bidSize': 800,
 'bookValue': 3.292,
 'category': None,
 'circulatingSupply': None,
 'city': 'Alachua',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.02,
 'dayLow': 5.6265,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.666,
 'enterpriseToRevenue': 24.806,
 'enterpriseValue': 70919912,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.8074284,
 'fiftyTwoWeekHigh': 10.42,
 'fiftyTwoWeekLow': 2.29,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 19892605,
 'forwardEps': -1.85,
 'forwardPE': -3.145946,
 'fromCurrency': None,
 'fullTimeEmployees': 85,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00932,
 'heldPercentInstitutions': 0.48185003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1561852800,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/agtc.com',
 'longBusinessSummary': 'Applied Genetic Technologies Corporation, a '
                        'clinical-stage biotechnology company, develops '
                        'transformational genetic therapies for patients '
                        'suffering from rare and debilitating diseases. The '
                        "company's advanced product candidates consist of "
                        'three ophthalmology development programs across two '
                        'targets, including X-linked retinitis pigmentosa, '
                        'which is in Phase I/II clinical trials; and '
                        'achromatopsia that is in Phase I/II clinical trials. '
                        'The company also has initiated one preclinical '
                        'program in otology and three preclinical programs in '
                        'targeting central nervous system disorders, including '
                        'one in adrenoleukodystrophy. Applied Genetic '
                        'Technologies Corporation has collaboration agreements '
                        'with Synpromics Limited and University of Florida; '
                        'Bionic Sight, LLC; and Otonomy, Inc. The company was '
                        'founded in 1999 and is headquartered in Alachua, '
                        'Florida.',
 'longName': 'Applied Genetic Technologies Corporation',
 'market': 'us_market',
 'marketCap': 149955792,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_7604030',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -41903000,
 'nextFiscalYearEnd': 1625011200,
 'open': 5.76,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '386 462 2204',
 'previousClose': 5.79,
 'priceHint': 2,
 'priceToBook': 1.7679223,
 'priceToSalesTrailing12Months': 52.450436,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.02,
 'regularMarketDayLow': 5.6265,
 'regularMarketOpen': 5.76,
 'regularMarketPreviousClose': 5.79,
 'regularMarketPrice': 5.76,
 'regularMarketVolume': 249997,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 25765600,
 'sharesPercentSharesOut': 0.1145,
 'sharesShort': 2949163,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 926297,
 'shortName': 'Applied Genetic Technologies Co',
 'shortPercentOfFloat': 0.1153,
 'shortRatio': 4.99,
 'startDate': None,
 'state': 'FL',
 'strikePrice': None,
 'symbol': 'AGTC',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.181,
 'twoHundredDayAverage': 5.0544243,
 'volume': 249997,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.agtc.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '32615'}